Ameriprise’s Immix Biopharma IMMX Stock Holding History

Ameriprise’s Portfolio IMMX Stock Details IMMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-452,147	Closed	-$2.36M	–	4145
2025 Q4	$2.36M	Buy	+452,147	New	+$1.86M	﹤0.01%	2915

Other funds holding IMMX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Ameriprise's IMMX Position: Q1 2026 in Review

Ameriprise sold out of Immix Biopharma (IMMX) in Q1 2026, closing a stake of 452,147 shares — an estimated $2.36M sold.

Ameriprise first reported a position in IMMX in Q4 2025 and held it in 1 quarter. The position peaked at $2.36M in Q4 2025. 77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

Ameriprise reported no remaining Immix Biopharma position as of Q1 2026 after selling out during the quarter.
Ameriprise sold 452,147 Immix Biopharma shares in Q1 2026, an estimated $2.36M.
Ameriprise first reported a position in Immix Biopharma in Q4 2025 and held it in 1 quarter.
Ameriprise's Immix Biopharma position peaked at $2.36M in Q4 2025.
77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.